G006151

UHPLC/MS Analysis of Antineoplastic and Antidepressant Drugs in Plasma on Titan^™ C18 after SPE using HybridSPE^®-PLus

application for HPLC, application for SPE

Properties

• technique(s): HPLC: suitable; solid phase extraction (SPE): suitable
• test parameters: sample/matrix: rat plasma; SPE well plate: HybridSPE-PLus 96-Well Plate, 50 mg/2 mL per well (575659-U); sample preparation: final analyte concentration 50 ng/mL; sample addition: 400 μL of 1% formic acid acetonitile:spiked plasma (3:1) per well; column: Titan C18, 5 cm x 2.1 mm I.D., 1.9 μm particles (577122-U); mobile phase: [A] 5 mM ammonium formate; [B] 5 mM ammonium formate in 90:10 (v:v) acetonitrile:water; gradient: 35 to 90% B in 1.5 min, held at 90% B for 0.4 min; flow rate: 0.4 mL/min; pressure: 3582 psi (247 bar); column temp.: 35 °C; detector: TOF/MS; injection: 1 μL
• suitability: application for HPLC; application for SPE
• application(s): pharmaceutical (small molecule)

Description

Analysis Note

HybridSPE-Phospholipid plates removed plasma-derived proteins and phospholipids to maximize LC/MS sensitivity. Titan C18 U/HPLC columns provided rapid resolution. The highest grade LC-MS solvents were used to supply low background interference and low particulate contaminants for robust, trouble-free operation. Cerilliant CRMs provided reliable identification and quantification.

Legal Information

HybridSPE is a registered trademark of Merck KGaA, Darmstadt, Germany

Analyte

Fluoxetine hydrochloride solution, 1.0 mg/mL in methanol (as free base), ampule of 1 mL, certified reference material, Cerilliant^®
Tamoxifen, ≥99%